Dec 19, 2022

Dr. David Huang is Senior VP and Chief Medical Officer at Peptilogics and working to change the approach for treating and reducing reinfection rates of periprosthetic joint infection, PJI. Their lead highly charged peptide PLG0206 has been shown to be broad spectrum and active against multi-drug resistant bacteria, common causes of PJI. Peptilogics' AI/ML platform is accelerating peptide discovery to reach better clinical candidates in therapeutic areas such as rare diseases, immuno-oncology, and immunology.

David explains, "Peptilogics' approach to changing the treatment paradigm for treating PJI is by treating PJI directly at the site of infection. Instead of administering an antibiotic systemically or by mouth, as mentioned earlier, Peptilogics has an engineered cationic peptide and an irrigation solution that can be administered directly to the site of infection in the wound cavity of the knee, for example. The knee does not have a great blood supply. Therefore, antibiotics given intravenously or by mouth have a difficult time getting to the site of infection in the knee."

"Peptilogics' lead peptide called PLG0206 is an engineered cationic antibacterial peptide, which has orphan drug QIDP, which stands for qualified infectious disease product, and fast track designation from the FDA. And the way that PLG works is by its novel mechanism of action. It selectively binds to and disrupts the integrity of the bacterial membrane by altering the physical characteristics of the membrane, leading to a rapid loss of the bacterial cell membrane potential that results in cell death."

@Peptilogics #Peptilogics #PJI #PeriprostheticJointInfection #Peptides

Peptilogics.com

Listen to the podcast here